Ionis Pharmaceuticals, Inc.
IONS US4622221004
Ionis Pharmaceuticals is the leading developer of antisense technology to discover and develop novel drugs. Its broad clinical and preclinical pipeline targets a wide variety of diseases, with an emphasis on cardiovascular, metabolic, neurological, and rare diseases. Ionis and partner Biogen brought Spinraza to market in 2016 as a treatment for a rare neuromuscular disorder, spinal muscular atrophy, and Biogen launched ALS drug Qalsody in 2023. Ionis brought two additional drugs to market via its cardiovascular-focused subsidiary Akcea, including ATTR amyloidosis drug Tegsedi (2018) and cardiology drug Waylivra (Europe, 2019).
Annual Performance 1
| 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| -46% | 16% | 35% | -34% | 0% |
Annual Insiders Turnover, USD 2
1 annual and historical performance metrics are recalculated on a daily basis;
2 represents the total value of insider transactions (both buying and selling);
Insider Activity
| Person | Price | Shares | Total | Published | Completed |
|---|---|---|---|---|---|
| O'neil Patrick R. EX VP |
69.27 USD |
3,241 Sold |
224,488 USD |
06/10/2025 | 06/10/2025 |
| Monia Brett P CEO |
69.26 USD |
437 Sold |
30,268 USD |
06/10/2025 | 06/10/2025 |
| Swayze Eric EX VP |
69.02 USD |
6,849 Sold |
472,718 USD |
06/10/2025 | 06/10/2025 |
| O'neil Patrick R. EX VP |
69.89 USD |
10,200 Sold |
712,849 USD |
06/10/2025 | 06/10/2025 |
| Baroldi Joseph EX VP |
69.37 USD |
1,625 Sold |
112,725 USD |
06/10/2025 | 06/10/2025 |
| O'neil Patrick R. EX VP |
67.69 USD |
30,203 Sold |
2,044,417 USD |
02/10/2025 | 02/10/2025 |
| Swayze Eric EX VP |
66.23 USD |
12,972 Sold |
859,082 USD |
01/10/2025 | 02/10/2025 |
| Baroldi Joseph EX VP |
68.01 USD |
15,000 Sold |
1,020,210 USD |
02/10/2025 | 02/10/2025 |
| O'neil Patrick R. EX VP |
67.69 USD |
34,461 Sold |
2,332,638 USD |
02/10/2025 | 02/10/2025 |
| Swayze Eric EX VP |
66.09 USD |
14,142 Sold |
934,662 USD |
01/10/2025 | 01/10/2025 |